Pharmaceuticals News and Research

RSS

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Biothera announced today that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms.

10 Mar 2011

Columbia fourth quarter total net revenues increase 74% to $14.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and twelve-month periods ended December 31, 2010.

10 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, today announces that it has signed a Research and License Agreement with Crucell Holland B.V. the Dutch developer of vaccines and antibodies.

10 Mar 2011

Scientists identify chemical compound that may lead to cancer-fighting drugs

Researchers at UT Southwestern Medical Center have identified a chemical compound that may eventually lead to a drug that fights cancers that are dependent on a particular anti-viral enzyme for growth.

10 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

10 Mar 2011

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced today that the US Food and Drug Administration (FDA) has accepted its Extended Release Carbinoxamine Oral Suspension NDA for the treatment of allergies in kids two years and older. If approved, Tris Pharma's Extended Release Suspension will provide an alternative to the currently available immediate release formulations.

10 Mar 2011

Opinions: Investing in science, technology; Indian public-private partnership for NTDs; U.S. global food security investments; Clinton's statements on PEPFAR; U.S. foreign aid; primary care

"Now is the time to support science and technology - especially in difficult economic times. It is the right thing to do, and it makes good economic sense," Alex Dehgan, science and technology adviser to the USAID administrator, and Kaitlin Christenson, coalition director for the Global Health Technologies Coalition, write in an opinion piece appearing on The Hill's "Congress Blog."

10 Mar 2011

NextGen Group subsidiary completes commercial reorganization

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has completed a commercial reorganization. The restructuring, which is accompanied by new management appointments, is expected to help the company execute its strategy of becoming a leading player in the growing oncology and central nervous system (CNS) biomarker markets.

10 Mar 2011

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

Kamada, a biopharmaceutical company developing, manufacturing and marketing specialty life-saving therapeutics, announced today it has received an Israeli Patent for its Ultrapure Transferrin to be used in Pharmaceutical Compositions.

10 Mar 2011

NCPA encourages patients on safe disposal of unwanted medications

In recognition of Patient Safety Awareness Week, the National Community Pharmacists Association encourages patients to properly dispose of expired or unwanted medications at a local independent community pharmacy as part of its Dispose My Meds program.

10 Mar 2011

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

TARIS Biomedical, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS' innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC.

10 Mar 2011

PPD introduces new online portal to enhance patient connectivity, improve retention in clinical trials

PPD, Inc. today announced it has launched an innovative online portal linking clinical trial participants with biopharmaceutical companies, physicians and health care resources to enhance patient connectivity and improve retention in clinical trials.

10 Mar 2011

FDA accepts Merck's SAFLUTAN NDA for standard review

Merck, known as MSD outside the United States and Canada, announced today that the New Drug Application for SAFLUTAN, Merck's investigational preservative-free prostaglandin analogue ophthalmic solution, has been accepted for standard review by the U.S. Food and Drug Administration.

10 Mar 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, today announced that the first injectable product using EDT's NanoCrystal technology has been approved by the European Commission.

9 Mar 2011

U.S. FDA approves Hospira's docetaxel to treat variety of cancers

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere, and Hospira expects to launch the product later this month.

9 Mar 2011

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX for the treatment of Peyronie's disease.

9 Mar 2011

New Australian drug approvals subject to budget cuts

According to Health Minister Nicola Roxon’s statement to pharmaceutical company bosses, new medicines will no longer be subsidised unless budget savings can be found.

9 Mar 2011

Pharmaceuticals News and Research

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Columbia fourth quarter total net revenues increase 74% to $14.9 million

Idera reports $6.0 million net loss for fourth quarter 2010

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Scientists identify chemical compound that may lead to cancer-fighting drugs

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

Opinions: Investing in science, technology; Indian public-private partnership for NTDs; U.S. global food security investments; Clinton's statements on PEPFAR; U.S. foreign aid; primary care

NextGen Group subsidiary completes commercial reorganization

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

NCPA encourages patients on safe disposal of unwanted medications

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

PPD introduces new online portal to enhance patient connectivity, improve retention in clinical trials

FDA accepts Merck's SAFLUTAN NDA for standard review

EDT receives European approval for XEPLION injection to treat schizophrenia

U.S. FDA approves Hospira's docetaxel to treat variety of cancers

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

New Australian drug approvals subject to budget cuts

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence